Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice

References

• Khazaei S, Soleimani M, Tafti SHA, Aghdam RM, Hojati Z. Improvement of Heart Function After Transplantation of Encapsulated Stem Cells Induced with miR-1/Myocd in Myocardial Infarction Model of Rat. Cell Transplant. 2021;30:9636897211048786. doi:10.1177/09636897211048786
   Web of Science ®Google Scholar
• Goudhaman L, Raja Jagadeesan A, Sundaramoorthi S, Thotla S, Krishna Mohan S. Association of Serum Asymmetric Dimethylarginine with the Severity of Coronary Artery Disease: a Pilot Study. Rep Biochem Mol Biol. 2021;10(2):302–306. doi:10.52547/rbmb.10.2.302
   PubMed Web of Science ®Google Scholar
• Berinstein E, Levy A. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. Expert Opin Drug Metab Toxicol. 2017;13(9):973–983. doi:10.1080/17425255.2017.1363887
   PubMed Web of Science ®Google Scholar
• Amar J. Microbiota-Host Crosstalk: a Bridge Between Cardiovascular Risk Factors, Diet, and Cardiovascular Disease. Am J Hypertens. 2018;31(8):941–944. doi:10.1093/ajh/hpy067
   PubMed Web of Science ®Google Scholar
• Francula-Zaninovic S, Nola IA. Management of Measurable Variable Cardiovascular Disease’ Risk Factors. Curr Cardiol Rev. 2018;14(3):153–163. doi:10.2174/1573403X14666180222102312
   PubMed Web of Science ®Google Scholar
• van Dongen LH, de Goede P, Moeller S, et al. Temporal variation in out-of-hospital cardiac arrest occurrence in individuals with or without diabetes. Resusc Plus. 2021;8:100167. doi:10.1016/j.resplu.2021.100167
   PubMedGoogle Scholar
• Moore KJ, Shah R. Introduction to the Obesity, Metabolic Syndrome, and CVD Compendium. Circ Res. 2020;126(11):1475–1476. doi:10.1161/CIRCRESAHA.120.317240
   PubMed Web of Science ®Google Scholar
• Pang S, Song P, Sun X, et al. Dietary fructose and risk of metabolic syndrome in Chinese residents aged 45 and above: results from the China National Nutrition and Health Survey. Nutr J. 2021;20(1):83. doi:10.1186/s12937-021-00739-9
   PubMed Web of Science ®Google Scholar
• Liu SS, Kim JY, Park JH, et al. Fruit Intake and Changes of Cardio-Metabolic Risk Factors in People with Obesity. Korean J Fam Med. 2021;42(5):382–389. doi:10.4082/kjfm.20.0205
   PubMed Web of Science ®Google Scholar
• van der Velden AIM, van den Berg BM, de Mutsert R, et al. Microvascular differences in individuals with obesity at risk of developing cardiovascular disease. Obesity. 2021;29(9):1439–1444. doi:10.1002/oby.23222
   PubMed Web of Science ®Google Scholar
• Sagaro GG, Battineni G, Di Canio M, Amenta F. Self-Reported Modifiable Risk Factors of Cardiovascular Disease among Seafarers: a Cross-Sectional Study of Prevalence and Clustering. J Pers Med. 2021;11(6):512. doi:10.3390/jpm11060512
   PubMed Web of Science ®Google Scholar
• Juli L, Juli R, Juli G, Juli MR. New Therapeutic Strategies for Eating Disorders and Obesity Treatment. Psychiatr Danub. 2021;33(Suppl 9):84–85.
   PubMedGoogle Scholar
• Rayner CK, Jones KL, Horowitz M. Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity. JAMA. 2021;326(12):1213–1214. doi:10.1001/jama.2021.13021
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Bassock S, Engels E, et al. Semaglutide single-dose pen-injector: post hoc analysis of summative usability testing for weight management. Diabetes Obes Metab. 2021;23(11):2590–2594. doi:10.1111/dom.14509
   PubMed Web of Science ®Google Scholar
• Chen Y, Wei D, Deng M. Comparative Analysis of Serum Proteins Between Hepatitis B Virus Genotypes B and C Infection by DIA-Based Quantitative Proteomics. Infect Drug Resist. 2021;14:4701–4715. doi:10.2147/IDR.S335666
   PubMed Web of Science ®Google Scholar
• Moulder R, Schvartz D, Goodlett DR, Dayon L. Proteomics of Diabetes, Obesity, and Related Disorders. Proteomics Clin Appl. 2018;12(1):845. doi:10.1002/prca.201600134
   Web of Science ®Google Scholar
• López-Villar E, Martos-Moreno GÁ, Chowen JA, Okada S, Kopchick JJ, Argente J. A proteomic approach to obesity and type 2 diabetes. J Cell Mol Med. 2015;19(7):1455–1470. doi:10.1111/jcmm.12600
   PubMed Web of Science ®Google Scholar
• Hanash S. Disease proteomics. Nature. 2003;422(6928):226–232. doi:10.1038/nature01514
   PubMed Web of Science ®Google Scholar
• Xu L, Yu Y, Sang R, Li J, Ge B, Zhang X. Protective Effects of Taraxasterol against Ethanol-Induced Liver Injury by Regulating CYP2E1/Nrf2/HO-1 and NF-κB Signaling Pathways in Mice. Oxid Med Cell Longev. 2018;2018:8284107. doi:10.1155/2018/8284107
   PubMed Web of Science ®Google Scholar
• Pan X, Chen X, Ren Q, et al. Single-cell transcriptome reveals effects of semaglutide on non-cardiomyocytes of obese mice. Biochem Biophys Res Commun. 2022;622:22–29. doi:10.1016/j.bbrc.2022.07.034
   PubMed Web of Science ®Google Scholar
• Vileigas DF, Harman VM, Freire PP, et al. Landscape of heart proteome changes in a diet-induced obesity model. Sci Rep. 2019;9(1):18050. doi:10.1038/s41598-019-54522-2
   PubMed Web of Science ®Google Scholar
• Pan X, Chen S, Chen X, et al. UTP14A, DKC1, DDX10, PinX1, and ESF1 Modulate Cardiac Angiogenesis Leading to Obesity-Induced Cardiac Injury. J Diabetes Res. 2022;2022:2923291. doi:10.1155/2022/2923291
   PubMed Web of Science ®Google Scholar
• le Roux CW, Hartvig NV, Haase CL, Nordsborg RB, Olsen AH, Satylganova A. Obesity, cardiovascular risk and healthcare resource utilization in the UK. Eur J Prev Cardiol. 2021;28(11):1235–1241. doi:10.1177/2047487320925639
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, Phase 2 trial. Lancet. 2018;392(10148):637–649. doi:10.1016/S0140-6736(18
   PubMed Web of Science ®Google Scholar
• Piché ME, Tchernof A, Després JP. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020;126(11):1477–1500. doi:10.1161/CIRCRESAHA.120.316101
   PubMed Web of Science ®Google Scholar
• Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovasc Res. 2017;113(4):389–398. doi:10.1093/cvr/cvx012
   PubMed Web of Science ®Google Scholar
• Kolijn D, Pabel S, Tian Y, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovasc Res. 2021;117(2):495–507. doi:10.1093/cvr/cvaa123
   PubMed Web of Science ®Google Scholar
• Watanabe K, Nagao M, Toh R, et al. Critical role of glutamine metabolism in cardiomyocytes under oxidative stress. Biochem Biophys Res Commun. 2021;534:687–693. doi:10.1016/j.bbrc.2020.11.018
   PubMed Web of Science ®Google Scholar
• Alpert MA, Omran J, Bostick BP. Effects of Obesity on Cardiovascular Hemodynamics, Cardiac Morphology, and Ventricular Function. Curr Obes Rep. 2016;5(4):424–434. doi:10.1007/s13679-016-0235-6
   PubMed Web of Science ®Google Scholar
• Harada T, Obokata M. Obesity-Related Heart Failure with Preserved Ejection Fraction: pathophysiology, Diagnosis, and Potential Therapies. Heart Fail Clin. 2020;16(3):357–368. doi:10.1016/j.hfc.2020.02.004
   PubMed Web of Science ®Google Scholar
• Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020;229:61–69. doi:10.1016/j.ahj.2020.07.008
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409–418. doi:10.1016/j.diabet.2018.12.001
   PubMed Web of Science ®Google Scholar
• Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020;22(8):1263–1277. doi:10.1111/dom.14054
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841–851. doi:10.1056/NEJMoa1901118
   PubMed Web of Science ®Google Scholar
• Bain SC, Mosenzon O, Arechavaleta R, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21(3):499–508. doi:10.1111/dom.13553
   PubMed Web of Science ®Google Scholar
• Liśkiewicz AD, Marczak Ł, Bogus K, Liśkiewicz D, Przybyła M, Lewin-Kowalik J. Proteomic and Structural Manifestations of Cardiomyopathy in Rat Models of Obesity and Weight Loss. Front Endocrinol. 2021;12:568197. doi:10.3389/fendo.2021.568197
   PubMed Web of Science ®Google Scholar
• Pan LC, Xiao HY, Yin WJ, Lin Z. Correlation between HSD17B4 expression in rat liver cancer tissues and inflammation or proliferation. Eur Rev Med Pharmacol Sci. 2018;22(11):3386–3393. doi:10.26355/eurrev_201806_15160
   PubMed Web of Science ®Google Scholar
• Huang H, Liu R, Huang Y, et al. Acetylation-mediated degradation of HSD17B4 regulates the progression of prostate cancer. Aging. 2020;12(14):14699–14717. doi:10.18632/aging.103530
   PubMedGoogle Scholar
• Yamashita S, Hattori N, Fujii S, et al. Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy. Sci Rep. 2020;10(1):15530. doi:10.1038/s41598-020-72661-9
   PubMed Web of Science ®Google Scholar
• Pyun JA, Kim S, Cha DH, Ko JJ, Kwack K. Epistasis between the HSD17B4 and TG polymorphisms is associated with premature ovarian failure. Fertil Steril. 2012;97(4):968–973. doi:10.1016/j.fertnstert.2011.12.044
   PubMed Web of Science ®Google Scholar
• Neess D, Kruse V, Marcher AB, et al. Epidermal Acyl-CoA-binding protein is indispensable for systemic energy homeostasis. Mol Metab. 2021;44:101144. doi:10.1016/j.molmet.2020.101144
   PubMed Web of Science ®Google Scholar
• Bravo-San Pedro JM, Sica V, Martins I, et al. Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. Cell Metab. 2019;30(4):754–767.e9. doi:10.1016/j.cmet.2019.07.010
   PubMed Web of Science ®Google Scholar
• Charmpilas N, Ruckenstuhl C, Sica V, et al. Acyl-CoA-binding protein (ACBP): a phylogenetically conserved appetite stimulator. Cell Death Dis. 2020;11(1):7. doi:10.1038/s41419-019-2205-x
   PubMed Web of Science ®Google Scholar
• Oikari S, Ahtialansaari T, Heinonen MV, et al. Downregulation of PPARs and SREBP by acyl-CoA-binding protein overexpression in transgenic rats. Pflugers Arch. 2008;456(2):369–377. doi:10.1007/s00424-007-0416-y
   PubMed Web of Science ®Google Scholar
• Melchior JT, Street SE, Vaisar T, et al. Apolipoprotein A-I modulates HDL particle size in the absence of apolipoprotein A-II. J Lipid Res. 2021;62:100099. doi:10.1016/j.jlr.2021.100099
   PubMed Web of Science ®Google Scholar
• Koike T, Koike Y, Yang D, et al. Human apolipoprotein A-II reduces atherosclerosis in knock-in rabbits. Atherosclerosis. 2021;316:32–40. doi:10.1016/j.atherosclerosis.2020.11.028
   PubMed Web of Science ®Google Scholar
• Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261(5120):469–472. doi:10.1126/science.8332912
   PubMed Web of Science ®Google Scholar
• Castellani LW, Gargalovic P, Febbraio M, Charugundla S, Jien ML, Lusis AJ. Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II. J Lipid Res. 2004;45(12):2377–2387. doi:10.1194/jlr.M400345-JLR200
   PubMed Web of Science ®Google Scholar
• Li MY, Wang Y, Lei X, et al. Molecular characterization of a catalase gene from the green peach aphid (Myzus persicae). Arch Insect Biochem Physiol. 2021;108(2):e21835. doi:10.1002/arch.21835
   PubMed Web of Science ®Google Scholar
• Liang L, Shou XL, Zhao HK, et al. Antioxidant catalase rescues against high fat diet-induced cardiac dysfunction via an IKKβ-AMPK-dependent regulation of autophagy. Biochim Biophys Acta. 2015;1852(2):343–352. doi:10.1016/j.bbadis.2014.06.027
   PubMed Web of Science ®Google Scholar
• Gao J, Xie Q, Wei T, Huang C, Zhou W, Shen W. Nebivolol improves obesity-induced vascular remodelling by suppressing NLRP3 activation. J Cardiovasc Pharmacol. 2019. doi:10.1097/FJC.0000000000000667
   Web of Science ®Google Scholar
• Kim HR, Choi EJ, Kie JH, Lee JH, Seoh JY. Deficiency of glutathione peroxidase-1 and catalase attenuated diet-induced obesity and associated metabolic disorders. Acta Diabetol. 2020;57(2):151–161. doi:10.1007/s00592-019-01388-5
   PubMed Web of Science ®Google Scholar
• Rindler PM, Plafker SM, Szweda LI, Kinter M. High dietary fat selectively increases catalase expression within cardiac mitochondria. J Biol Chem. 2013;288(3):1979–1990. doi:10.1074/jbc.M112.412890
   PubMed Web of Science ®Google Scholar
• Yıldırım S, Akar S, Kuyucu M, Yıldırım A, Dane S, Aygül R. Paraoxonase 1 gene polymorphisms, paraoxonase/arylesterase activities and oxidized low-density lipoprotein levels in patients with migraine. Cell Biochem Funct. 2011;29(7):549–554. doi:10.1002/cbf.1785
   PubMed Web of Science ®Google Scholar